Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Euronext Growth Paris  >  Cellectis    ALCLS   FR0010425595


Real-time Quote. Real-time Euronext Growth Paris - 01/26 11:35:29 am
25.55 EUR   +0.59%
01/20European ADRs Edge Lower in Wednesday Trading
01/19European ADRs Move Higher in Tuesday Trading
01/14European ADRs Climb Higher in Thursday Trading
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Cellectis : Is the distribution phase coming to an end ?

04/14/2020 | 04:11am EST
long trade
Target price hit
Entry price : 8.97€ | Target : 10.75€ | Stop-loss : 8.25€ | Potential : 19.84%
After accumulation, acceleration. Timing appears favorable to go long in shares of Cellectis and to anticipate an exit of the trading range on the upside.
Investors have an opportunity to buy the stock and target the € 10.75.
Cellectis : Cellectis : Is the distribution phase coming to an end ?
  • The company usually posts poor financials for mid or long term investments.
  • The company has poor fundamentals for a short-term investment strategy.

  • The share is getting closer to its long-term support in weekly data, at EUR 7.38, which offers good timing for buyers.
  • Graphically speaking, the timing seems perfect for purchasing the stock close to the EUR 7.38 support.
  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

  • The company has insufficient levels of profitability.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • With an enterprise value anticipated at 3.71 times the sales for the current fiscal year, the company turns out to be overvalued.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • The technical configuration over the long term remains negative on the weekly chart below the resistance level at 11.41 EUR

© MarketScreener.com 2020
Stocks mentioned in the article
ChangeLast1st jan.
AT HOME GROUP INC. 3.31% 25.9 Delayed Quote.62.16%
BYD COMPANY LIMITED 9.35% 278.4 End-of-day quote.37.01%
CELLECTIS 0.59% 25.55 Real-time Quote.4.10%
CHANGE INC. 8.49% 3770 End-of-day quote.6.95%

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Sales 2020 53,4 M 65,0 M 65,0 M
Net income 2020 -74,3 M -90,4 M -90,4 M
Net cash 2020 161 M 196 M 196 M
P/E ratio 2020 -9,28x
Yield 2020 -
Capitalization 1 093 M 1 329 M 1 330 M
EV / Sales 2020 17,4x
EV / Sales 2021 15,1x
Nbr of Employees 259
Free-Float 83,2%
Income Statement Evolution
Mean consensus BUY
Number of Analysts 2
Average target price 27,35 €
Last Close Price 25,55 €
Spread / Highest target 14,3%
Spread / Average Target 7,05%
Spread / Lowest Target -0,20%
EPS Revisions
Managers and Directors
André Choulika Chief Executive Officer
Jean-Pierre Garnier Non-Executive Chairman
Eric Dutang Chief Financial Officer
Philippe Duchateau Chief Scientific Officer
Francisco J. Esteva Vice President-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
CELLECTIS4.10%1 318
MODERNA, INC.40.71%58 169
LONZA GROUP AG6.79%50 766
CELLTRION, INC.-10.58%39 697
SEAGEN INC.2.84%32 583